PRKN and small cell lung carcinoma: METTL3 induces the degradation of decapping protein 2 (DCP2), resulting in reduced inhibition of PINK1 and Parkin with enhanced mitophagy, alleviated tumor cell dysfunction levels and increased chemotherapy resistance in small cell lung cancer (SCLC) [79].